摘要
目的 :观察地氯雷他定治疗慢性荨麻疹的疗效和安全性。方法 :采取随机对照临床试验 ,试验组每日口服地氯雷他定 5mg,疗程 2周 ;对照组每日口服咪唑斯汀 1 0mg,疗程 2周。结果 :共治疗1 5 6例 ,试验组 81例 ,对照组 75例 ,试验组总有效率为 88 9% ,对照组为 86 6% ,两组总有效率比较差异无显著性 (P >0 0 5 ) ;不良反应发生率试验组为 1 0 9% ,对照组为 9 3 % ,两组比较差异无显著性 (P>0 0 5 )。结论 :地氯雷他定是一种治疗慢性荨麻疹较安全有效的药物。
Objective:To observe the clinical efficacy and safety of desloratadine in treatment of chronic urticaria. Methods:A randomly comparative study was conducted. The patients were randomly divided into two groups:receive desloratadine (5 mg) in study group or mizolastine (10 mg) in control once daily for two weeks. Results:156 patients completed the trial,including 81 cases in desliratadine group and 75 cases in mizolasline group. The effective rate of desloratadine and mizolastine group were 88.9% and 86.6% respectively, No statistical significance was observed between two groups (P>0.05) after two weeks treatment. The incidences of adverse reaction of desloratadine and mizolastine were 10.9% and 9.3% respectively, There were no statistical significance between two groups (P>0.05). Conclusion:Desloratadine is an effective and safe drug in treatment of chronic urticaria.
出处
《岭南皮肤性病科杂志》
2004年第2期130-132,共3页
Southern China Journal of Dermato-Venereology
